Carl J Danzig, M.D., F.A.S.R.S.
Carl J Danzig, M.D., F.A.S.R.S., is a board-certified ophthalmologist and vitreoretinal surgeon with extensive experience in the diagnosis and treatment of retinal diseases.
Dr. Danzig earned a B.A. in Philosophy from Tulane University before returning to his hometown of Philadelphia to attend medical school at Temple University. After completing his internship in Philadelphia, he spent a year conducting intraocular tumor research at Wills Eye Hospital. He then completed his ophthalmology residency at SUNY Downstate Medical Center in Brooklyn, followed by a two-year fellowship in vitreoretinal surgery at the University of Texas Southwestern Medical Center in Dallas.
He has built a distinguished career in clinical research, academic medicine, and patient care. In private practice, he founded the retina department at Rand Eye Institute and served as Principal Investigator for 59 clinical trials. He also helped bring investigational retinal gene therapy to South Florida through a clinical trial evaluating novel treatments for geographic atrophy.
Internationally recognized for his contributions to retinal research, he is a sought-after speaker at conferences and lectures worldwide and remains at the forefront of advances in retinal care, bringing innovative therapies to patients. He has authored numerous scientific publications, serves as a peer reviewer for leading ophthalmology journals, and continues to advance the field through research and education.
Dr. Danzig is a member of the Retina Society and is actively involved in several leading ophthalmology organizations. He serves as Chair of the Instructional Course on Geographic Atrophy for the American Academy of Ophthalmology, Affiliate Assistant Professor of Clinical Biomedical Science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and an incoming Board Member of the Florida Society of Ophthalmology.
Fluent in English and proficient in Spanish, he is committed to providing personalized, compassionate care while offering patients access to the latest advances in retinal treatment.
Dr. Danzig adores his wife and three children, and he has a passion for travel and has visited 67 countries, including all Seven New Wonders of the World.
EDUCATION
UNDERGRADUATE EDUCATION
- Tulane University, New Orleans, LA
- Bachelor of Science, 1996-2000
MEDICAL EDUCATION
- Temple University of Medicine, Philadelphia, PA
- Doctor of Medicine, 2000–2004
INTERNSHIP
- Crozer-Chester Medical Center, Upland, PA
- Department of Medicine, 2004-2005
RESIDENCY
- Martin Luther King, Jr. Hospital/Charles R. Drew University, Los Angeles, CA
- Department of Ophthalmology, 2006-2007
- SUNY-Downstate, Brooklyn, NY
- Chief Resident, 2007-2009
FELLOWSHIP
- Wills Eye Hospital, Philadelphia, PA
- Research Department of Ocular Oncology
- University of Texas Southwestern Medical Center, Dallas, TX
- Department of Ophthalmology, 2009-2011
LICENSES
- Florida State License
- Texas State License
ORGANIZATIONS
- American Academy of Ophthalmology
- American Society of Retina Specialists
- Retina Society
- Association for Vision Research and Ophthalmology
- Vit-Buckle Society
- Asociación Colombiana Retina y Vitreo
PROFESSIONAL CERTIFICATIONS
- Association for Research in Vision and Ophthalmology, National Eye Institute Travel Grant, 2007
- American Society of Retina Specialists, Honor Award, 2023
- American Academy of Ophthalmology– Editorial Board of ONE Network, Retina Section, 2016-2021
- American Society of Retina Specialists- Fellow
AFFILIATIONS
- Assistant Professor of Clinical Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University
PUBLICATIONS
- Khanani AM, Danzig CJ, Heier JS, Jaffee GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG. Avancaptad pegol for Geographic Atrophy Secondary to Age- Related Macular Degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial. Ophthalmology. 2025 Dec 15. Epub ahead of print.
- Danzig CJ, Dinah C, Ghanchi F, Hattanbach LO, Khanani AM, Lai T, Shimura M, Abreau F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann P. Faricimab Treat-and-Extend Dosing for Macular Edema due to Retina Vein Occlusion: 72-Week Results from the BALATAN and COMINO Trials. Ophthal Retina 2025 Sep; 9(9):848-859
**Additional publications are available upon request**
